To the editor,
In the recent review of myeloproliferative neoplasms (MPN), Helbig summarizes the current evidence of how the three major types of MPN driver mutations (JAK2 V617F, CALR exon 9 and MPL exon 10) influence disease phenotype and impact on prognosis. In this review, it is stated that these three mutation types are mutually exclusive [1] . However, in addition to an increased annotation of cases in which an MPN harbouring one of these types of mutations co-exists with BCR-ABL1-positive chronic myeloid leukemia [2] , there is a growing awareness that a combination of any two of these types of mutations can occur concurrently in a minor, but significant proportion of patients with the classical MPN of polycythemia vera, essential thrombocythemia and primary myelofibrosis. In one of the largest series reported to date, double-mutant MPN appear to possess specific presenting features, dependent on which of the two mutations are present [3] .
Coincident with this increasing appreciation of the double-mutant MPN entity is the consequence for MPN molecular diagnostics.
Step-wise algorithms for the JAK2 V617F, CALR and MPL mutations in which once a mutation is detected no further analysis is performed must now be reconsidered. Simultaneous identification of the three driver mutations by targeted next-generation sequencing approaches would largely overcome this issue and would likely enhance identification of further cases, necessary for stratified risk-assessment and selection of treatment.
